Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Achieve Life Sciences
Female patients with first or second line metastatic breast cancer will be randomized to receive either weekly TOCOSOL Paclitaxel or weekly Taxol (paclitaxel injection). Patients will undergo radiographic imaging of their disease to assess response to therapy. The primary endpoint of this study is a comparison of the objective response rates observed in patients receiving TOCOSOL Paclitaxel, to those receiving Taxol. Time-to-disease progression and overall survival will also be compared. The toxicities of the two treatment regimens will be compared.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Patients with histologic diagnosis of breast carcinoma
Stage IV (M1) disease
Adult (18 years of age or older) patients
You may not be if
Patients treated with a taxane within the past year
Patients whose tumor tissue is known to show over expression of HER2/neu
